Skip to content

A clinical study on the efficacy and safety of pursuing irradiation in stereotactic body radiotherapy for the lung

A clinical study on the efficacy and safety of pursuing irradiation in stereotactic body radiotherapy for the lung - The efficacy and safety of pursuing irradiation in SBRT for the lung

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000005324
Enrollment
35
Registered
2011-06-01
Start date
2011-06-01
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lung cancer

Interventions

Pursing irradiation in SBRT with 48 Gy or 56Gy in 4 fractions, once a day, twice to four times a week

Sponsors

Department of Radiation Oncology and Image-applied Therapy, Graduate School of Medicine, Kyoto University
Lead Sponsor
Mitsubishi Heavy Industries, Ltd
Collaborator

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Primary or metastatic lung cancer A. Primary lung cancer; (1) (a) Prinmary lung cancer, with histological and/or cytological confirmation, (b) clinically or radiologically diagnosed lung cancer (2) Tumor size </= 5cm, and clinical stage IA or IB B. Metastatic lung cancer; (1)Metastatic lung cancer clinically or radiologically diagnosed (2)Tumor size </=5cm, a single lung lesion, and no lesions other than lung 2) Dose to adjacent organ is not estimated to exceed constraints in pretreatment chest CT 3) Patients' age must be>/=≥20 years old 4) ECOG performance status must be 0-2 5) Patients can lay on their back holding their arms over the heads, and keep that position at least 30 minutes 6) Estimated tumor movement due to respitation >/=5mm

Exclusion criteria

Exclusion criteria: 1) previous irradiation around the lesion 2) With active interstitial pneumonia or pulmonary fibrosis 3) With severe diabetic mellitus or collagen disease 4) Women during pregnancy or lactating , or who might be pregnant 5) With psychiatric illness which impede protocol treatment 6) Patients who are considered to be inappropriate for this study by physicians

Design outcomes

Primary

MeasureTime frame
Feasibility of the protocol treatment

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026